[PRACTICE NOTE] Journey Operations for Field Excellence

Executive Context


Pharma commercial organizations have never been more sophisticated at shaping prescribing intent. Omnichannel orchestration operates with precision. Data infrastructure enables personalization at scale. Artificial intelligence informs targeting, sequencing, and next best actions with a level of technical maturity that would have been inconceivable a decade ago. By conventional measures of commercial advancement, the front end of the commercial engine has never been stronger.


Yet a persistent and economically significant structural gap remains between prescribing intent and realized patient care delivery.


The constraint is not selling effectiveness. It is not insufficient promotional intensity. It is not a lack of effort, technology, or engagement discipline. The constraint resides in what happens after the script is written, when clinical conviction must navigate the operational complexity of modern healthcare.


Field and omnichannel models have industrialized influence. They have mastered reach, cadence, coverage, and engagement rigor. They have optimized exposure and refined the mechanisms that shape healthcare professional decision making. What has not been industrialized with equal discipline is the follow through across the end to end journeys that determine whether prescribing intent becomes therapy initiation, sustained adherence, and captured revenue.


The commercial system remains architected to shape decisions at the front end. It is not consistently structured to ensure progression once those decisions enter the terrain of payer variability, documentation burden, affordability constraints, specialty pharmacy coordination, and fragmented internal handoffs.


The result is not a deficit of activity. It is the steady accumulation of barriers across the Path to Prescribe, Path to Fulfill, and Path to Adhere.


Clinical conviction is formed. Prescriptions are written. The science is trusted. By traditional commercial measures, the moment has been won and momentum should follow. Instead, progression becomes fragile. Access complexity slows initiation. Administrative burden fragments continuity. Documentation rework multiplies. Pharmacy reversals recur. Escalations become patterned rather than episodic.


Friction accumulates quietly. Delays extend initiation timelines. Abandonment risk rises. Revenue leakage forms not as a dramatic collapse but as a compounding sequence of small breakdowns that erode value over time. The enterprise continues to generate intent with increasing precision, yet realization remains structurally vulnerable.


This is the Intent to Impact Gap.


It emerges when clinical conviction fails to endure the realities of access, fulfillment, and adherence pathways that were never architected as the primary unit of commercial performance. It widens when continuity is treated as downstream variability rather than as an explicit commercial responsibility embedded within the field operating model. The organization measures activity rigorously while leaving progression exposed.


Closing this gap cannot be accomplished through incremental refinement of field enablement, additional coaching interventions, targeting adjustments, or messaging optimization. Those efforts strengthen persuasion at the moment of influence. They do not stabilize realization once the decision enters the healthcare delivery system.


What is required is structural evolution.


The commercial operating model must shift from conventional Field Operations, organized around activity and coverage, to Journey Operations, organized around end to end progression and realization. In this paradigm, the unit of performance is no longer the call, the campaign, or the detail. It is the sustained movement of prescribing intent through the Path to Prescribe, Path to Fulfill, and Path to Adhere until realization is secured in patient care.


Journey Operations reframes field performance from generating exposure to protecting progression. It embeds barrier mitigation, structured frontline listening, bespoke journey measurement, and continuous improvement directly into commercial cadence. It makes realization visible, measurable, and manageable as a core commercial variable rather than an assumed downstream outcome.


This shift does not occur through aspiration, pilot initiatives, or dashboard overlays. It requires architectural clarity, disciplined implementation, and a redefinition of what commercial excellence means in a consumer grade healthcare environment.


FieldOS™ is introduced in this paper as the reference architecture that enables this transition. It provides the blueprint for restructuring field performance around realization, reducing revenue leakage, stabilizing progression, and protecting the full value of the prescribing intent the enterprise works so hard to create.


Journeys as the Engine of Value Realization


In contemporary commerce, the foundational unit of value realization is the journey.


A brand establishes expectation. A product promises outcome. A campaign stimulates action. Yet value is only realized when individuals successfully move from need to outcome across a defined sequence of interactions. That sequence is the journey. It determines whether trust strengthens or erodes, whether adherence stabilizes or declines, whether revenue compounds or leaks.


Every high-performing industry organizes around its core realization journeys. Finance protects liquidity through Order to Cash. Supply chains protect margin through integrated sourcing and production journeys. Digital commerce engineers Browse to Buy and Purchase to Delivery to secure conversion and repeat behavior. These are not conceptual diagrams. They are structural engines of realization, continuously governed because they determine enterprise stability.


Pharma possesses equivalent structural journeys. They simply have not always been architected and operated with comparable discipline.


  • Path to Prescribe governs how clinical conviction becomes prescribing intent.
  • Path to Fulfill governs how prescribing intent becomes initiated therapy.
  • Path to Adhere governs how initiated therapy becomes sustained therapy.


Together, these journeys form the structural spine of clinical and commercial realization. When they are fragmented, intent dissipates. When they are engineered and operated with rigor, scientific excellence translates into durable patient impact.


The Strategic Imperative for Pharma and Life Sciences


In regulated, high stakes industries such as pharma, the implications of this shift are profound. The enterprise must navigate scientific rigor, compliance constraints, payer variability, and distributed service models while meeting rising expectations shaped by consumer experiences outside healthcare.


Healthcare professionals increasingly benchmark their professional interactions against the clarity, responsiveness, and continuity they experience in other parts of their lives. Patients bring similar expectations into their treatment journeys. When those expectations are unmet, trust erodes and adherence declines.


The path forward is not more activity. It is greater coherence.


The enterprise must intentionally design and operate journeys that convert conviction into initiation, initiation into adherence, and adherence into durable outcomes. This requires discipline across two interlocking domains. Journey Design establishes the structural integrity of progression. Journey Operations ensures that the structure performs at speed, at standard, and at scale under real world conditions.


Only when structure and operations reinforce one another does scientific excellence translate reliably into sustained patient impact.


Executive Takeaways.


1. The Enterprise Has Optimized Intent Creation, Not Value Capture.

Commercial sophistication has increased materially, yet the conversion of prescribing intent into realized revenue remains structurally vulnerable. The gap is architectural, not tactical.


2. Revenue at Risk Is Embedded in Downstream Variability.

Barrier-heavy journeys across access, fulfillment, and adherence create silent leakage. Small instability across initiation or persistence compounds into significant lifetime value erosion.


3. Current Performance Systems Overweight Activity, Underweight Realization.

Dashboards track reach, engagement, and coverage with precision. Progression reliability and continuity risk are not governed with equal rigor.


4. Journeys Are the Commercial Infrastructure of Realization.

Path to Prescribe, Path to Fulfill, and Path to Adhere function as enterprise value chains. When engineered and operated intentionally, they stabilize forecast reliability and protect capital efficiency.


5. The Required Shift Is Structural, Not Incremental.

Closing the Intent-to-Impact Gap requires redefinition of commercial performance around progression durability, barrier mitigation, and governed continuity — not incremental enablement refinement.


Questions to Consider.


1. What percentage of generated prescribing intent fails to convert into sustained revenue, and how confidently can we quantify it?

2. Where is Customer Value at Risk concentrated across our core realization journeys?

3. How does progression instability affect forecast confidence and capital deployment efficiency?

4. Do we treat access, fulfillment, and adherence continuity as governed commercial variables or as downstream variability?

5. What structural authority exists today to continuously identify and mitigate systemic barriers to realization?


By Wayne Simmons March 15, 2026
Why Customer Excellence is emerging as the discipline that turns scientific innovation into real-world impact. Pharmaceutical science has never been stronger. Pipelines are more diverse, clinical development more precise, and manufacturing more advanced than at any point in history. Yet amid this extraordinary progress the industry faces a defining paradox. Scientific excellence has accelerated dramatically, while the experiences through which that science reaches physicians and patients have not kept pace. The next chapter of commercial excellence will not be won by companies that merely communicate their science more efficiently. It will belong to organizations that deliver it more meaningfully. The companies that lead the next era of healthcare will treat customer experience with the same rigor as clinical efficacy, ensuring that every engagement becomes living proof of their science, their purpose, and their credibility. For decades the pharmaceutical industry has set the evidentiary standard for science and the trust standard for its brands. What now emerges as the next frontier is an experiential standard capable of matching both. Only when the experience of engaging with a company reflects the same precision, credibility, and consistency that govern its science will the full value of innovation reach the people it is intended to serve. This evolution begins with Customer Excellence , the discipline that unites marketing, sales, and launch excellence into a coherent commercial operating system capable of earning both permission and preference. From Science as Foundation to Experience as Fulfillment Science remains the foundation and heartbeat of the pharmaceutical enterprise. It drives the Path-to-Prescribe, where evidence, education, and clinical outcomes shape physician confidence and influence treatment decisions. Yet even the most extraordinary science cannot fulfill its promise unless it moves successfully through the broader system that surrounds the prescribing moment. Once a therapy is recommended, the journey continues through the Path-to-Fulfill , where access, affordability, operational coordination, and patient readiness determine whether a prescription ultimately becomes therapy in the patient’s hands. Across this journey, friction, administrative burden, and fragmented processes frequently erode impact and delay treatment initiation. Sustained outcomes then depend on the Path-to-Adhere , where patient support, education, monitoring, and continuity of care determine whether individuals remain on therapy long enough to realize its intended clinical benefit. The therapeutic value created in the laboratory is only fully realized when patients are able to begin treatment and stay on it with confidence. Clinical innovation can demonstrate efficacy, but experience determines whether that efficacy becomes reality. The journey from lab to life depends on what occurs before, during, and long after the moment of prescription. Before prescribing, healthcare professionals form impressions of credibility, clarity, and relevance. At the point of decision, trust and confidence influence uptake. Afterward, access, patient readiness, and ongoing support sustain adherence and belief in the therapy. In some therapeutic areas, as many as half of prescriptions go unfulfilled or therapies discontinued prematurely. This is rarely a failure of science. It is more often a failure of system design, where burden-heavy and friction-heavy journeys make it difficult for healthcare professionals to initiate and sustain therapy for their patients. Pharma has long set the benchmark for scientific evidence and brand trust. What is now required is an experiential standard equal to those same heights, ensuring that engagement with the company feels as credible, coherent, and confidence-inspiring as the science itself. Science drives the Path to Prescribe. Experience shapes the Path to Fulfill. Sustained engagement enables the Path to Adhere. Together, these journeys define the new frontier of Customer Excellence. Why Transformation Is No Longer Enough Transformation has become the default response to nearly every commercial challenge. Digital transformation, omnichannel transformation, and now AI transformation have each promised to close the gap between companies and their customers. Yet despite billions invested across platforms, data systems, and engagement technologies, the experiences delivered to healthcare professionals often remain inconsistent, impersonal, and disconnected. The issue is not intent but orientation. Transformation modernizes tools, yet rarely challenges the mental models that define success. Organizations become more efficient at executing familiar patterns rather than reimagining how value should be delivered.Pharma does not require another transformation initiative. What it requires is a disciplined reinvention that questions the orthodoxy of activity metrics, channel proliferation, and functional isolation while restoring coherence and humanity to how the industry delivers its science to the world. Customer Excellence as a Rebellion Customer Excellence represents that shift. It is a disciplined and systemic redefinition of how value is created, delivered, and sustained. Rather than measuring progress through scale and speed alone, it positions coherence, trust, and ease as the true measures of commercial excellence. This shift is not a rebellion against compliance but against complacency. It challenges leaders to move beyond optimization toward orchestration, building organizations where the quality of engagement reflects the quality of the science itself. The Seven Shifts Defining the Discipline The seven shifts form the architecture of Customer Excellence, uniting marketing, sales, and launch excellence into a single human-centered model for sustainable growth. Shift 1. From Tangible to Intangible Value Exchange Customers increasingly evaluate companies through intangible dimensions such as trust, relevance, and ease. Experiential Commerce has elevated these factors from soft considerations to structural drivers of enterprise value. Shift 2. From Campaign-Centric to Customer-Centric Journeys Marketing can no longer rely on episodic campaigns alone. Value is created across continuous journeys where engagement extends far beyond the initial promotional moment. Shift 3. Experience as a Third Pillar of Value Product and brand may attract attention, but experience determines whether relationships endure. Organizations that integrate experience alongside product and brand create a far more resilient value proposition. Shift 4. From Transactions to Relationships Customer health must be measured over time. Longitudinal relationships built on trust ultimately drive sustainable commercial performance. Shift 5. From Funnel to Flywheel Growth no longer ends at conversion. Customer Excellence transforms disconnected interactions into a compounding cycle of engagement, trust, and expansion. Shift 6. From Neutral Interactions to Brand-Defining Moments Every interaction communicates brand character. Thoughtfully designed experiences become evidence of reliability and partnership. Shift 7. From Vertical Silos to Horizontal Journeys Customers experience companies horizontally across journeys, not vertically through internal functions. Customer Excellence realigns organizations to reflect this reality. From Rebellion to System The seven shifts describe how pharmaceutical organizations can close the gap between scientific mastery and the lived experiences that bring that science to life across the full continuum of care. Customer Excellence does not replace Marketing Excellence, Sales Excellence, or Launch Excellence . It integrates them. Together these disciplines form a unified, customer-aligned commercial operating system capable of translating scientific promise into real-world clinical and commercial impact. Within this system, marketing shapes the scientific narrative that informs the Path to Prescribe. Sales brings that narrative to life through trusted engagement with healthcare professionals. Launch orchestrates the critical moments that accelerate adoption. Customer Excellence ensures that the experience surrounding the therapy enables succes s across the Path to Fulfill and the Path to Adhere, where access, support, and sustained engagement determine whether therapeutic value is ultimately realized. This is the next chapter of commercial excellence in pharma. It moves the industry beyond transformation toward orchestration, beyond scale toward coherence, and beyond message toward meaning. Science drives the Path to Prescribe. Experience shapes the Path to Fulfill. Sustained engagement enables the Path to Adhere. Customer Excellence unites all three. Science earns permission. Experience sustains belief. Customer Excellence earns both. Key Takeaways The future of differentiation in healthcare is experiential. Scientific innovation remains essential, but the experiences surrounding therapies increasingly determine whether that innovation achieves its intended impact. Customer Excellence represents the structural response to this shift. By integrating marketing, sales, launch excellence, and service functions into a coherent operating system, organizations can translate scientific value into lived value. Trust is no longer assumed simply because a therapy demonstrates clinical efficacy. It is built through the design, coherence, and consistency of the experiences that surround prescribing, access, and patient support. Transformation initiatives may modernize tools, yet genuine change occurs when organizations replace compliance-driven thinking with a deeper conviction about the centrality of the customer. Science earns permission through evidence, while experience earns preference through delivery. Together they form the foundation of enduring growth in the era of Experiential Commerce. Diagnostic Questions to Consider As the commercial model evolves, leadership teams must confront several difficult questions. Are we still benchmarking our engagement against other pharma companies, or against the best experiences healthcare professionals encounter in their everyday lives? Where does friction persist across the real journeys of prescribing, access, and patient adherence, and how clearly do we understand the barriers preventing clinical intent from translating into treatment? Do our commercial systems reinforce the promise of our science and brand, or do they introduce complexity that quietly undermines them? Have our investments in digital platforms, omnichannel engagement, and artificial intelligence reduced the cognitive burden on healthcare professionals, or simply multiplied the number of touchpoints they must navigate? A re we organized around internal functions and campaigns, or around the journeys through which physicians and patients actually experience our therapies? Most importantly, are we building organizations that only aspire to be customer-centric , or enterprises that are structurally designed to deliver customer excellence? Closing Reflection The pharma and life sciences industry has mastered the science of discovery and the discipline of evidence. The next era of leadership will belong to companies that apply that same rigor to the experiences through which science reaches the world. When organizations align their commercial systems with the realities of modern customer expectations, innovation no longer struggles in the final mile between prescription and patient care. Instead it arrives with clarity, coherence, and confidence. Your breakthrough science deserves experiences worthy of it. Together, we turn customer excellence into real-world impact. About the Author Wayne Simmons is a customer excellence strategist and founder of The Customer Excellence Agency, where he partners with pharmaceutical and life sciences leaders to turn customer-centric ambition into durable commercial advantage. He previously served as Global Customer Excellence Lead within Pfizer’s Chief Marketing Organization and has held leadership roles with Bayer Pharmaceuticals and The Ritz-Carlton Leadership Center. Wayne writes The Customer-Centric Marketer newsletter and is the author of The Customer Excellence Enterprise: A Playbook for Creating Customers for Life. The Customer Excellence Agency: Advancing the Pursuit of Excellence in Service of Science.
January 9, 2026
The Founding Philosophy of The Customer Excellence Agency Founded on the conviction that scientific brilliance only becomes human impact when excellence is engineered into leadership, culture, and experience delivery. This is a philosophy of rigor, responsibility, and reverence for the people science exists to serve.
December 29, 2025
[FAQs] The Customer Excellence Agency REFERENCE: Clear answers to the most common questions about Customer Excellence Activation, why it matters now, and how it works in practice.
Man speaking at a conference. Text: Pharma Customer Engagement USA. Colorful background.
By Wayne Simmons December 26, 2025
[PRACTICE NOTE] An Outsider’s Perspective, Earned from the Inside REFERENCE: “The Customer Excellence Enterprise: A Playbook for Creating Customers for Life”
A starbucks coffee sign hangs on the side of a building
By Wayne Simmons June 12, 2025
CASE-IN-POINT: Recapturing the Mystique: The Starbucks Customer Excellence Series Part 3  REFERENCE: “The Customer Excellence Enterprise: A Playbook for Creating Customers for Life” Commercial (COM) Bold Move #10: Create a New Brand Identity
Two men are working in a starbucks coffee shop.
By Wayne Simmons June 12, 2025
As often as it is mentioned in business literature, the idea of corporate culture can still seem intangible, amorphous, and even mysterious. Customer Excellence Enterprises have mastered the craft of clearly defining, documenting, and embedding their distinctive cultures at the DNA level through well-crafted culture platforms: * A culture “platform” is the foundation of its identity, embodying the shared values, principles, and practices that guide how it operates and interacts with the world. * Like the DNA of a living organism or the operating system of a computing device, culture platforms define the unique traits and essence of an organization, making it distinct from others. * To remain relevant and effective, a Starbucks culture platform must evolve to bridge the gap between the present and future while preserving authenticity, and timelessness.